Trial Profile
A Randomised, Double-Blind, Placebo-Controlled, Exploratory Phase IIa Study To Assess The Safety And Efficacy Of Orally Administered DS102 In NAFLD Patients
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 Oct 2022
Price :
$35
*
At a glance
- Drugs Epeleuton (Primary)
- Indications Non-alcoholic fatty liver disease
- Focus Adverse reactions; Therapeutic Use
- Sponsors Afimmune
- 23 Sep 2020 According to an Afimmune media release, Phase 2a data from this study was published in the peer-reviewed Journal of the American Heart Association (JAHA).
- 23 Sep 2020 Results presented in an Afimmune media release.
- 14 Nov 2019 According to an Afimmune media release, data from the study will be presented at the American Heart Association's (AHA) 2019 Scientific Sessions.